Research Paper Volume 13, Issue 11 pp 15413—15432

Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis

Overall survival hazard ratio in female patients in the immune checkpoint inhibitor group compared with the control group.

Figure 2. Overall survival hazard ratio in female patients in the immune checkpoint inhibitor group compared with the control group.